INFLUX Influx Healthtech Q4 FY26 results (Jan–Mar 2026) and concall
Influx Healthtech reported strong financial performance for H2 FY26, with significant revenue and PAT growth driven by nutraceuticals and ayurvedic products. The company is expanding its manufacturing capacity with a new 75,000 sq ft facility expected to be operational by July/August 2026, which will increase overall capacity by 2.5 times. Strategic reallocation of IPO proceeds is supporting this expansion, and the company aims for continued growth and margin maintenance in FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 48 | 57 | 67 | 80 |
| EBITDA | 9 | 11 | 15 | 15 |
| Net profit | 6 | 8 | 10 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
